Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine

Clinical and Experimental Immunology

Volumn 142, Issue 2, 2005, Pages 381-387

  Zuercher, A W ^a   Imboden, M A ^a   Jampen, S ^a   Bosse, Dietrich ^a   Ulrich, M ^a   Chtioui, H ^b   Lauterburg, B H ^b   Lang, A B ^a  

^a Berna Biotech AG   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cellular immunity; Conjugate vaccine; Human; Pseudomonas aeruginosa

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; POLYSACCHARIDE VACCINE; PSEUDOMONAS VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD ANALYSIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VACCINATION;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CELL PROLIFERATION; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; PSEUDOMONAS AERUGINOSA; T-LYMPHOCYTES; VACCINES, CONJUGATE;

EID: 27644446838     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02925.x     Document Type: Article

References (20)

1. Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancet 1993; 341:1065-9.
2. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15:194-222.
3. Cryz SJ Jr, Fuerer E, Cross AS et al. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest 1987; 80:51-6.
4. Cryz SJ Jr, Sadoff JC, Ohman D et al. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. J Lab Clin Med 1988; 111:701-7.
5. Cryz SJ Jr, Wedgewood J, Lang AB et al. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J Infect Dis 1994; 169:1159-62.
6. Cryz SJ Jr, Lang A, Rudeberg A et al. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst Mitt 1997; 98:345-9.
7. Schaad UB, Lang AB, Wedgwood J et al. Safety and immunogenicity of Pseudomonas aeruginosa polyvalent conjugate A vaccine in cystic fibrosis. Lancet 1991; 338:1236-7.
8. Lang AB, Schaad UB, Ruedeberg A et al. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 1995; 127:711-7.
9. Lang AB, Rüdeberg A, Schöni MH et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 2004; 23:504-10.
10. Johansen HK, Hougen HP, Cryz SJ Jr. et al. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Am J Respir Crit Care Med 1995; 152:1337-46.
11. Moser C, Johansen HK, Song Z et al. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS 1997; 105:838-42.
12. Moser C, Hougen HP, Song Z et al. Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS 1999; 107:1093-100.
13. Moser C, Kjaergaard S, Pressler T et al. The immune response to chronic Pseudomonas aeruginosa lung infection in cycstic fibrosis patients is predominantly of the Th2 type. APMIS 2000; 108:329-35.
14. 197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier. J Infect Dis 2003; 187:1629-38.
15. + T cell cytokine response that correlates with the isotype of antipolysaccharide antibody. J Infect Dis 2001; 184:931-5.
16. Wuorimaa T, Kayhty H, Eskola J et al. Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine. Scand J Immunol 2001; 53:422-8.
17. +-activated T cells in primary EBV infection. J Immunol 1999; 163:5735-40.
18. McElhaney JE, Pinkoski M, Meneilly GS. Changes in CD45 isoform expression vary according to the duration of T-cell memory vaccination. Clin Laboratory Diagn 1995; 2:73-81.
19. Zepp F, Knuf M, Habermehl P et al. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 1996; 64:4078-84.
20. + T cells upon NK T cell or T cell activation. J Immunol 2000; 165:4305-11.